Is GILD Close to a Generational Bottom?

Gilead Sciences GILD – NASDAQ

Thursday, May 18, 2017

Gilead Sciences GILD – NASDAQ has a very unique problem on its hands. Rather than requiring ongoing treatments, the biopharmaceutical company’s Hepatitis-C drugs cure the disease once and for all. Is being too good at the job why GILD has been stuck in a prolonged downtrend going on two years now?

According to a sharp trader who bought 10,000 GILD December 70 calls for $2.28 apiece earlier today, a turnaround is coming.


Costing $2.28 million, GILD has to increase 12.2% to the break-even price of $72.28 for this trade to pan out by expiration. With plenty of upside, it’s easy to envision GILD running up near $80. Our customer only needs a portion of this hypothetical situation, as he’s lined up to make a million bucks for every dollar GILD extends above $72.28.

CEO Buys $1 Million of Own Stock: “I believe in putting my money where my mouth is,” he said after making such a public splash. And to back it up, he just delivered the best Q1 in company history. Click here to get the stock.

Sign up for free research.

Enter your email to receive
Free Research